On March 15 Inhalation Sciences submitted an update of its listing plans for Ziccum AB, providing further clarification on many of the questions it received at the company presentation at Erik Penser Bank. Here, Ziccum Chairman and ISAB CEO Fredrik Sjövall answers everything you may need to know on the upcoming listing of Ziccum AB. Read More
On Wednesday 21 March Ziccum and ISAB CSO Per Gerde presents at the ‘New Updates in Drug Formulation & Bioavailability’ Conference in Copenhagen. Dr Gerde will speak on Ziccum’s flagship spray drying tool LaminarPace. Read More
Inhalation Sciences has updated its listing plans for Ziccum AB including schedule and a new preliminary valuation. Read More
For the first time Ziccum CEO Göran Conradsson presents the story of LaminarPace to investors and analysts at Stockholm’s prestigious Erik Penser Bank, Stockholm, March 15, 1200. But book early. Seats are limited.
Approx. 450 human antibodies are currently being developed to treat a wide range of diseases—but many are formulated as liquids, risking instability and attrition in clinical trials. Ziccum AB now releases full data from its recent proof-of-concept test showing how LaminarPace dries human antibodies into stable, active dry powders. The data include SEM (Scanning Electron Microscope) images, and more.
80% of human immunoglobulin antibodies, used to treat a wide range of diseases, are formulated as liquids, which can mean they are fragile, unstable and costly to transport. New results show that Ziccum AB’s spray drying instrument LaminarPace can produce a stable dry powder form of immunoglobulin antibodies—with confirmed activity. ‘This is an important milestone,’ says Ziccum CEO Göran Conradson.